רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה)

Country: Ísrael

Tungumál: hebreska

Heimild: Ministry of Health

Virkt innihaldsefni:

ROTAVIRUS G1 REASSORTANT; ROTAVIRUS G2 REASSORTANT; ROTAVIRUS G3 REASSORTANT; ROTAVIRUS G4 REASSORTANT; ROTAVIRUS P1A[8] REASSORTANT

Fáanlegur frá:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

ATC númer:

J07BH

Lyfjaform:

SUSPENSION

Samsetning:

ROTAVIRUS P1A[8] REASSORTANT 2.3 X10 ^6 IU/DOSE; ROTAVIRUS G2 REASSORTANT 2.8 X10 ^6 IU/DOSE; ROTAVIRUS G4 REASSORTANT 2.0 X10^ 6 IU/DOSE; ROTAVIRUS G3 REASSORTANT 2.2 X10 ^6 IU/DOSE; ROTAVIRUS G1 REASSORTANT 2.2 X10 ^6 IU/DOSE

Stjórnsýsluleið:

פומי

Gerð lyfseðils:

מרשם נדרש

Framleitt af:

MERCK SHARP & DOHME CORP., USA

Meðferðarhópur:

ROTA VIRUS DIARRHEA VACCINES

Ábendingar:

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RoraTeq should be administered betwen 6 and 12 weeks of age.

Leyfisdagur:

2022-05-31